Fundies. English
SpyGlass Pharma, Inc.
EDGAR5 filing records in this dataset, filed from 2026-01-16 to 2026-10-19. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 223 million USD Source
Exact value
223143000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 33.4 million shares Source
Exact value
33446315 shares
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-19.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2025-12-31
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- Current assets: 2 of 11 periods available· newest 2025-12-31
- Current liabilities: 2 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 10.71 millionPrior period
−USD 29.16 million
–
Current period
−USD 39.87 million
–
Exact inputs and evidence
-39869000 − -29164000 = -10705000 USD
-29164000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-39869000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 10.67 millionPrior period
−USD 22.03 million
–
Current period
−USD 32.7 million
–
Exact inputs and evidence
-32700000 − -22027000 = -10673000 USD
-22027000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-32700000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-60.4%Prior period
USD 1.99 million
–
Current period
USD 789,000
–
Exact inputs and evidence
789000 − 1991000 = -1202000 USD
1991000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source789000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −USD 29.16 million Exact valueExact value: -29164000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 22.03 million Exact valueExact value: -22027000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.99 million Exact valueExact value: 1991000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.02 million Calculation and evidence-22027000 − 1991000 USD Exact free cash flow: -24018000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 39.87 million Exact valueExact value: -39869000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 32.7 million Exact valueExact value: -32700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 789,000 Exact valueExact value: 789000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 33.49 million Calculation and evidence-32700000 − 789000 USD Exact free cash flow: -33489000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
5 filings · 296 latest values · 296 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001778922, 1778922, SGP, edgar:1778922
Also known as SpyGlass Ophthalmics, Inc., SpyGlass Pharma, Inc., SpyGlassPharma, Inc.